These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 37959808)

  • 1. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
    McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in antibody-drug conjugates for gynecologic malignancies.
    Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
    Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
    Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
    Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates in Gynecologic Cancers.
    Anastasio MK; Shuey S; Davidson BA
    Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
    Tymon-Rosario J; Zeybek B; Santin AD
    Curr Opin Obstet Gynecol; 2021 Feb; 33(1):26-33. PubMed ID: 32618744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals.
    McNamara B; Chang Y; Goreshnik A; Santin AD
    Int J Womens Health; 2023; 15():1353-1365. PubMed ID: 37663226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker.
    Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R
    J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating antibody drug conjugates in the management of gynecologic cancers.
    Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
    Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
    von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
    Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward a Ferrous Iron-Cleavable Linker for Antibody-Drug Conjugates.
    Spangler B; Kline T; Hanson J; Li X; Zhou S; Wells JA; Sato AK; Renslo AR
    Mol Pharm; 2018 May; 15(5):2054-2059. PubMed ID: 29569925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
    Duro-Sánchez S; Nadal-Serrano M; Lalinde-Gutiérrez M; Arenas EJ; Bernadó Morales C; Morancho B; Escorihuela M; Pérez-Ramos S; Escrivá-de-Romaní S; Gandullo-Sánchez L; Pandiella A; Esteve-Codina A; Rodilla V; Dijcks FA; Dokter WHA; Cortés J; Saura C; Arribas J
    Cancer Res; 2022 Dec; 82(24):4670-4679. PubMed ID: 36222720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
    Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
    Shi F; Liu Y; Zhou X; Shen P; Xue R; Zhang M
    Drug Deliv; 2022 Dec; 29(1):1335-1344. PubMed ID: 35506447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.